Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	46.80B -5.1%
Revenue (ttm)	7.29B +12.2%
Net Income	91.39M -69.1%
EPS	0.11 -69.2%
Shares Out	834.18M
PE Ratio	512.10
Forward PE	64.22
Dividend	0.13 (0.21%)
Ex-Dividend Date	Jul 10, 2026

Volume	16,307,210
Open	58.43
Previous Close	57.39
Day's Range	58.01 - 59.88
52-Week Range	35.57 - 67.85
Beta	0.35
Analysts	Buy
Price Target	60.86 (+3.17%)
Earnings Date	Aug 28, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,984
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2025, SHE:300347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Analyst Summary

According to 14 analysts, the average rating for 300347 stock is "Buy." The 12-month stock price target is ¥60.86, which is an increase of 3.17% from the latest price.

Price Target

¥60.86

(3.17% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 21, 2026

Data Sources Report a data error